Association of HLA-DRB3*0202 and serum IgG antibodies to Chlamydia pneumoniae with essential hypertension in a highly homogeneous population from Majorca (Balearic Islands, Spain).
Separate studies investigating the relationship of essential hypertension (EH) with the HLA system and with Chlamydia pneumoniae (C. pneumoniae) infection have given conflicting results. Our aim was to clarify these relationships and determine whether the HLA system and C. pneumoniae infection interact with respect to the risk for EH. An association study (110 essential hypertensives and 107 controls) was conducted in a highly homogeneous population in the Balearic Island of Majorca (Spain). Molecular typing of HLA-B and HLA-DRB and quantification of serum levels of IgG antibodies to C. pneumoniae (sIgGa-Cp) were determined. Student's t-test, chi(2)-statistics, logistic regression analysis, and general linear model ANOVA were used for statistical analysis. The results showed that EH was related with HLA-DRB3*0202 in the whole study population, and with levels of sIgGa-Cp>63.5 BU/ml in the group of individuals with sIgGa-Cp>30 BU/ml (OR (95% CI) adjusted for obesity, familial history of EH and diabetes=2.06 (1.07-3.97), P=0.03, and =4.60 (1.06-19.90), P=0.04, respectively). The association between EH and sIgGa-Cp was observed in the DRB3*0202(+) individuals, but not in the DRB3*0202(-) subgroup (OR (95% CI)=11.14 (1.92-64.54), P=0.004, and =0.98 (0.22-4.43), P=0.64, respectively (P of the Mantel-Haenszel test for homogeneity of OR=0.06)). In our population, EH was positively associated with HLA-DRB3*0202 and with high levels of sIgGa-Cp. Moreover, a significant interaction of DRB3*0202 on the effect of sIgGa-Cp was observed, as the association of EH with these antibodies depended on the presence of DRB*0202.
Zabay
J M
JM
Fundación Balear Transplant, Avda. Joan Miró 168, 07015 Palma de Mallorca, Spain.
Marco
J
J
Soler
J
J
Contu
L
L
Cappai
L
L
Carcassi
C
C
Gómez
G
G
Mulet
J M
JM
Munar
M A
MA
Viader
C
C
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D016022:Case-Control Studies; D023521:Chlamydophila Infections / Q000150:complications; D016993:Chlamydophila pneumoniae / Q000276:immunology*; D005260:Female; D015235:HLA-B Antigens / Q000235:genetics; D006684:HLA-DR Antigens / Q000235:genetics*; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000235:genetics* / Q000382:microbiology; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013030:Spain
D000907:Antibodies, Bacterial; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D007074:Immunoglobulin G